Data Monster
@EngBigData
Followers
2K
Following
123K
Media
5K
Statuses
35K
Big board swing trader focused on large-cap movements and market microstructure. Analyzing market volatility and sharing insights on equities and derivatives.
Raleigh, NC
Joined January 2018
Quit porn. Delete Snapchat. Stop following Instagram sluts. Read old books. Follow God. Win.
77
543
8K
My top plays to end 2025 and scale in Q1-Q2 2026. $HIMS Hims & Hers Health - Healthcare $UNH UnitedHealth Group - Healthcare $ZETA Zeta Global Holdings - Technology $OSCR Oscar Health - Healthcare $INTC Intel Corporation - Technology $UPS United Parcel - Service Industrials
1
0
0
Zeta Global Holdings Corp (NYSE: $ZETA) On the company's AI-driven return on ad spend (ROAS): Steinberg highlighted achieving a 6:1 ROAS, describing it as a key competitive moat in the MarTech industry. He stated that the goal is to reach 10:1 ROAS, emphasizing that this would
0
0
3
$NVO presents a compelling buy opportunity at its current valuation. Trading near a multi-year low with a P/E ratio around 12x, well below historical averages. Bolstered by a 2.6% dividend yield, robust revenue growth exceeding 20% YoY, and strong EPS expansion, $NVO stands out
0
0
2
$UPST Looking for a close over the 200 EMA over the next couple weeks. Same pattern, same channel. Don't overthink.
1
0
8
$VXIT
$VXIT this has been said for years about this stock and yet only a few hundred million shares have ever diluted since 2020. They also have only $25k-ish in convertible note debt. It's not hard to do more homework than a literal one second glance.
0
0
2
Chocolate Peanut Butter Toasted Old Fashioned 🥃 This decadent twist on the classic Old Fashioned combines the rich, nutty sweetness of Ballotin chocolate peanut butter whiskey with the caramelized, oaky depth of Yellowstone toasted bourbon. The result is a smooth, dessert-like
0
1
2
$HIMS Weekly Price Action Summary (Dec 8–12, 2025) Hims & Hers Health $HIMS experienced a volatile week, opening at $39.34 on December 8 and closing the week at $37.88 on December 12, marking a net decline of approximately 3.7% amid heightened trading volume. The stock initially
0
0
1
🇺🇸 President Trump says interest rates should be 1% or lower next year. #Bullish #bullishmomentum #Investing $SPY
0
0
0
Investment Considerations $NVO A "safe haven" at current levels—trading at 5-year lows with a 13x P/E and 2%+ yield—offering defensive growth (18% TTM revenue) and cash flow for buybacks/dividends (DKK 53B returned YTD). Ideal for value investors betting on rebound (analysts see
0
0
1
Business and Growth Comparison Revenue Drivers: $NVO derives 94% of sales from diabetes/obesity (H1 2025: $21.1B, +24% YoY), making it vulnerable to GLP-1 competition and patent cliffs (semaglutide expires 2031 in U.S.). $LLY cardiometabolic segment is 77% of revenue but
1
0
0
Novo Nordisk $NVO and Eli Lilly $LLY are leading pharmaceutical companies dominating the GLP-1 market for diabetes and obesity treatments. NVO's key products include Ozempic and Wegovy (semaglutide), while LLY's are Mounjaro and Zepbound (tirzepatide). In 2025, NVO has faced
1
0
0
$UPS looking for a test of the 200 EMA (Daily) to make a move higher in the $107 range
0
0
0
$JD patience is key here and it's testing mine... Looking for a double bottom bounce around $28.21 with a bounce to the downward trendline
0
0
1
$IGEX 9x the volume for 116,679,260 for today What did I miss?
0
0
7
Dow Jones Industrial Average hitting a fresh all-time high amid broad relief from the Federal Reserve's latest policy moves, while tech-heavy indices pulled back due to concerns over AI valuations sparked by Oracle's earnings report. The Fed cut its benchmark interest rate by 25
0
0
0
$UNH UnitedHealth Group is starting to get very strong support here at nearly $340. Expect to see $400 within the next month if it continues when tax loss selling is over.
17
26
190
$JD focus on the facts.
18
28
433